NCT04050761

A Study of Nivolumab in Patients With Head and Neck Cancer.

A French Prospective, Non-interventional Research ( NIR) of Nivolumab in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After a Platinum-based Therapy

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 502 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy

Conditions

• Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck

Interventions

Type	Name	Description
BIOLOGICAL	Nivolumab	Specified dose on Specific Days

Timeline

• Start date: 2019-06-26
• Primary completion: 2024-07-08
• Completion: 2024-07-08
• First posted: 2019-08-08
• Last updated: 2025-07-02

Locations

1 site across 1 country: France

Regulatory

• FDA-regulated drug study